Determination of imatinib in human plasma and its significance

( views:, downloads: )
ZHONG Jian-sheng(Department of Hematology, the Affiliated Nanfang Hospital of Nanfang Medical University, Guangzhou 510515, China)
MENG Fan-yi(Department of Hematology, the Affiliated Nanfang Hospital of Nanfang Medical University, Guangzhou 510515, China)
Journal Title:
Volume 19, Issue 01, 2010
Key Word:
Imatinib; Concentration; Significance

Abstract: As the first line of therapy for chronic myeloid leukemia, the outcome of imatinib is encouraging. The plasma concentration of imatinib is correlated with remission rate and survival, and affected by α1 acid glycoprotein(AGP) and those drugs which will change the activities of cytochrome P450(CYP3A4). It is conductive for the treatment of CML by monitoring the plasma concentration of imatinib.

  • [1]Cohen MH,Williams G,Johnson JR,et a].Approval summary for imatinib mesylate capsules in the treatment of chronic myelogenous leukemia.Clin Cancer Res,2002,8:935-942.
  • [2]Hochhaus A,Druker B,Sawyers C,et al.Favorable long-term follow-up results over 6 years for response,survival,and safety with imatinib mesylate therapy in chronic-phase chronic myeloid leukemia after failure of interferon-alpha treatment.Blood,2008,111:1039-1043.
  • [3]Palandri F,Castagnetti F,Alimena G,et al.The long-term durability of cytogenetic responses in patients with accelerated phase chronic myeloid leukemia treated with imatinib 600 mg:the G1MEMA CML Working Party experience after a 7-year follow-up.Haematologica,2009,94:205-212.
  • [4]Druker BJ,Guilhot F,0' Brien SG,et al.Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia.N Engl J Med,2006,355:2408-2417.
  • [5]Bianchini M,De Brasi C,Gargallo P,et al.Specific assessment of BCR -ABL transcript overexpression and imatinib resistance in chronic myeloid leukemia patients.Eur J Haematol,2008,.
  • [6]Druker BJ,Talpaz M,Resta DJ,et al.Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia.N Engl J Med,2001,344:1031-1037.
  • [7]Deininger MW,Goldman JM,Lydon N,et al.The tyrosine kinase inhibitor CGP57148B selectively inhibits the growth of BCR-ABL-positive cells.Blood,1997,90:3691-3698.
  • [8]Colombat M,Fort M P,Chollet C,et al.Molecular remission in chronic myeloid leukemia patients with sustained complete cytogenetic remission after imatinib mesylate treatment.Haematologica,2006,91:162-168.
  • [9]Picard S,Titier K,Etienne G,et al.Trough imatinib plasma levels are associated with both cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukemia.Blood,2007,109:3496-3499.
  • [10]Larson RA,Druker BJ,Guilhot F,et al.Imatinib pharmacokinetics and its correlation with response and safety in chronic-phase chronic myeloid leukemia:a subanalysis of the IRIS study.Blood,2008,111:4022-4028.
  • [11]Horikoshi A,Takei K,Sawada S.Relationship between daily dose of imatinib per square meter and its plasma concentration in patients with chronic-phase chronic myeloid leukemia (CML).Leuk Res,2007,31:574-575.
  • [12]Kantarjian H,Talpaz M,O'Brien S,et al.High-dose imatinib mesylate therapy in newly diagnosed Philadelphia chromosome-positive chronic phase chronic myeloid leukemia.Blood,2004,103:2873-2878.
  • [13]Cortes J,Talpaz M,O'Brien S,et al.Molecular responses in patients with chronic myelogenous leukemia in chronic phase treated with imatinib mesylate.Clin Cancer Res,2005,11:3425-3432.
  • [14]Cohen MH,Johnson JR,Pazdur R.U.S.Food and Drug Administration Drug Approval Summary:conversion of imatinib mesylate (STI571; Gleevec) tablets from accelerated approval to full approval.Clin Cancer Res,2005,11:12-19.
  • [15]Kantarjian HM,Larson RA,Guilhot F,et al.Efficacy of imatinib dose escalation in patients with chronic myeloid leukemia in chronic phase.Cancer,2009,115:551-560.
  • [16]Widmer N,Decosterd LA,Leyvraz S,et al.Relationship of imatinib-free plasma levels and target genotype with efficacy and tolerability.Br J Cancer,2008,98:1633-1640.
  • [17]Peng B,Lloyd P,Schran H.Clinical pharmacokinetics of imatinib.Clin Pharmacokinet,2005,44:879-894.
  • [18]Deininger MW,Druker BJ.Specific targeted therapy of chronic myelogenous leukemia with imatinib.Pharmacol Rev,2003,55:401-423.
  • [19]Ivanovic D,Medenica M,Jancic B,et al.Reversed-phase liquid chromatography analysis of imatinib mesylate and impurity product in Glivec capsules.J Chromatogr B Analyt Technol Biomed Life Sci,2004,800:253-258.
  • [20]Schleyer E,Pursche S,Kohne CH,et al.Liquid chromatographic method for detection and quantitation of STI-571 and its main metabolite N-desmethyl-STI in plasma,urine,cerebrospinal fluid,culture medium and cell preparations.J Chromatogr B Analyt Technol Biomed Ufe Sci,2004,799:23-36.
  • [21]Velpandian T,Mathur R,Agarwal NK,et al.Development and validation of a simple liquid chromatographic method with ultraviolet detection for the determination of imatinib in biological samples.J Chromatogr B Analyt Technol Biomed Life Sci,2004,804:431-434.
  • [22]Vivekanand VV,Sreenivas RD,Vaidyanathan G,et al.A validated LC method for imatinib mesylate.J Pharm Biomed Anal,2003,33:879-889.
  • [23]Widmer N,Beguin A,Rochat B,et al.Determination of imatinib (Gleevec) in human plasma by solid-phase extraction-liquid chromatography-ultraviolet absorbance detection.J Chromatogr B Analyt Technol Biomed Life Sci,2004,803:285-292.
  • [24]Bakhtiar R,Khemani L,Hayes M,et al.Quantification of the anti-leukemia drug STI571 (Gleevec) and its metabolite (CGP 74588) in monkey plasma using a semi-automated solid phase extraction procedure and liquid chromatography-tandem mass spectrometry.J Pharm Biomed Anal,2002,28:1183-1194.
  • [25]Bakhtiar R,Lohne J,Ramos L,et al.High-throughput quantification of the anti-leukemia drug STI571 (Gleevec) and its main metabolite (CGP 74588) in human plasma using liquid chromatography-tandem mass spectrometry.J Chromatogr B Analyt Technol Biomed Life Sci,2002,768:325-340.
  • [26]Parise RA,Ramanathan RK,Hayes MJ,et al.Liquid chromatographic-mass spectrometric assay for quantitation of imatinib and its main metabolite (CGP 74588) in plasma.J Chromatogra B,Analyt Technol Biomed Cfe Sci,2003,791:39-44.
  • [27]Titier K,Picard S,Ducint D,et al.Quantification of imatinib in human plasma by high-performance liquid chromatography-tandem mass spectrometry.Ther Drug Monit,2005,27:634-640.
  • [28]Oostendorp RL,Beijnen JH,Schellens JH,et al.Determination of imatinib mesylate and its main metabolite (CGP74588) inhuman plasma and murine specimens by ion-pairing reversed-phase high-performance liquid chromatography.Biomed Chromatogr,2007,21:747-754.
  • [29]Fournier T,Medjoubi-N N,Porquet D.Alpha-1-acid glycoprotein.Biochim Biophys Acta,2000,1482:157-171.
  • [30]Gibbons J,Egorin MJ,Ramanathan RK,et al.Phase I and pharmacokinetic study of imatinib mesylate in patients with advanced malignancies and varying degrees of renal dysfunction:a study by the National Cancer Institute Organ Dysfunction Working Group.J Clin Oncol,2008,26:570-576.
  • [31]Le CP,Kreuzer KA,Na IK,et al.Determination of alpha-1 acid glycoprotein in patients with Ph~+ chronic myeloid leukemia during the first 13 weeks of therapy with STI571.Blood Cells Mol Dis,2002,28:75-85.
  • [32]Gambacorti-Passerini C,Zucchetti M,Russo D,et al.Alphal acid glycoprotein binds to imatinib (ST1571) and substantially alters its pharmacokinetics in chronic myeloid leukemia patients.Clin Cancer Res,2003,9:625-632.
  • [33]Gambacorti-Passerini C,Bami R,Le C P,et al.Role of alphal acid glycoprotein in the in vivo resistance of human BCR-ABL (+) leukemic cells to the abl inhibitor STI571.J Natl Cancer Inst,2000,92:1641-1650.
  • [34]Gambacorti-Passerini C B,Rossi F,Verga M,et al.Differences between in vivo and in vitro sensitivity to imatinib of Bcr/Abl + cells obtained from leukemic patients.Blood Cells Mol Dis,2002,28:361-372.
  • [35]Larghero J,Leguay T,Mourah S,et al.Relationship between elevated levels of the alpha 1 acid glycoprotein in chronic myelogenous leukemia in blast crisis and pharmacological resistance to imatinib (Gleevec) in vitro and in vivo.Biochem Pharmacol,2003,66:1907-1913.
  • [36]Bolton AE,Peng B,Hubert M,et al.Effect of rifampicin on the pharmacokinetics of imatinib mesylate (Gleevec,STI571) in healthy subjects.Cancer Chemother Pharmacol,2004,53:102-106.
  • [37]Druker BJ,Sawyers CL,Capdeville R,et al.Chronic myelogenous leukemia.Hematology Am Soc Hematol Educ Program,2001:87-112.
  • [38]O'Brien S,Meinhardt P,Bond E,et al.Effects of imatinib mesylate (ST1571,Glivec) on the pharmacokinetics of simvastatin,a cytochrome p450 3A4 substrate,in patients with chronic myeloid leukaemia.Br J Cancer,2003,89:1855-1859.
  • [39]Deininger MW,O'Brien S,Ford JM,et al.Practical management of.patients with chronic myeloid leukemia receiving imatinib.J Clin Oncol,2003,21:1637-1647.
WanfangData CO.,Ltd All Rights Reserved
About WanfangData | Contact US
Healthcare Department, Fuxing Road NO.15, Haidian District Beijing, 100038 P.R.China
Tel:+86-010-58882616 Fax:+86-010-58882615